company background image
NSB

NeuroScientific BiopharmaceuticalsASX:NSB Stock Report

Market Cap

AU$57.4m

7D

0%

1Y

29.0%

Updated

20 Oct, 2021

Data

Company Financials
NSB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NSB Overview

NeuroScientific Biopharmaceuticals Limited develops diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies.

Price History & Performance

Summary of all time highs, changes and price drops for NeuroScientific Biopharmaceuticals
Historical stock prices
Current Share PriceAU$0.40
52 Week HighAU$0.20
52 Week LowAU$0.54
Beta0.012
1 Month Change-10.11%
3 Month Change21.21%
1 Year Change29.03%
3 Year Change150.00%
5 Year Changen/a
Change since IPO77.78%

Recent News & Updates

Oct 07
NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans

NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Jun 23
Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. Indeed, NeuroScientific...

Mar 10
Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

NSBAU BiotechsAU Market
7D0%1.1%1.7%
1Y29.0%1.7%20.2%

Return vs Industry: NSB exceeded the Australian Biotechs industry which returned 1.7% over the past year.

Return vs Market: NSB exceeded the Australian Market which returned 20.2% over the past year.

Price Volatility

Is NSB's price volatile compared to industry and market?
NSB volatility
NSB Beta0.012
Industry Beta1.62
Market Beta1

Stable Share Price: NSB is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: NSB's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002n/aMatt Liddelowhttps://www.neuroscientific.com

NeuroScientific Biopharmaceuticals Limited develops diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies. The company’s lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Cottesloe, Australia.

NeuroScientific Biopharmaceuticals Fundamentals Summary

How do NeuroScientific Biopharmaceuticals's earnings and revenue compare to its market cap?
NSB fundamental statistics
Market CapAU$57.39m
Earnings (TTM)-AU$3.18m
Revenue (TTM)AU$958.77k

59.9x

P/S Ratio

-18.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NSB income statement (TTM)
RevenueAU$958.77k
Cost of RevenueAU$39.60k
Gross ProfitAU$919.17k
ExpensesAU$4.10m
Earnings-AU$3.18m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.022
Gross Margin95.87%
Net Profit Margin-331.45%
Debt/Equity Ratio0.0%

How did NSB perform over the long term?

See historical performance and comparison

Valuation

Is NeuroScientific Biopharmaceuticals undervalued compared to its fair value and its price relative to the market?

3.93x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NSB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NSB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NSB is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: NSB is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NSB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NSB is good value based on its PB Ratio (3.9x) compared to the AU Biotechs industry average (4.8x).


Future Growth

How is NeuroScientific Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NeuroScientific Biopharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has NeuroScientific Biopharmaceuticals performed over the past 5 years?

-41.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NSB is currently unprofitable.

Growing Profit Margin: NSB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NSB is unprofitable, and losses have increased over the past 5 years at a rate of 41.8% per year.

Accelerating Growth: Unable to compare NSB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NSB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).


Return on Equity

High ROE: NSB has a negative Return on Equity (-21.76%), as it is currently unprofitable.


Financial Health

How is NeuroScientific Biopharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: NSB's short term assets (A$14.4M) exceed its short term liabilities (A$223.4K).

Long Term Liabilities: NSB has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: NSB is debt free.

Reducing Debt: NSB had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NSB has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: NSB has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 44.5% each year


Dividend

What is NeuroScientific Biopharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NSB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NSB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NSB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NSB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NSB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Matt Liddelow

3.67yrs

Tenure

AU$435,530

Compensation

Mr. Matthew Liddelow, BSc, M. Pharm, also known as Matt, serves as Chief Executive Officer, Managing Director & Director of NeuroScientific Biopharmaceuticals Limited. Mr. Liddelow has experience in the co...


CEO Compensation Analysis

Compensation vs Market: Matt's total compensation ($USD325.63K) is about average for companies of similar size in the Australian market ($USD302.06K).

Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: NSB's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: NSB's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 82.6%.


Top Shareholders

Company Information

NeuroScientific Biopharmaceuticals Limited's employee growth, exchange listings and data sources


Key Information

  • Name: NeuroScientific Biopharmaceuticals Limited
  • Ticker: NSB
  • Exchange: ASX
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$57.389m
  • Shares outstanding: 143.47m
  • Website: https://www.neuroscientific.com

Location

  • NeuroScientific Biopharmaceuticals Limited
  • 85 Forrest Street
  • Suite 5
  • Nedlands
  • Western Australia
  • 6011
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 15:35
End of Day Share Price2021/10/20 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.